Skip to main content

Table 1 Descriptive data of participants

From: Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study

Variable Final participants (n = 53)
Mean age (SD) [years] 38.42 (8.77)
Sex (female:male) 45:8
Comorbidity (%) None: 43 (81.13)
HTN/CV: 3 (5.66)
Hypothyroidism: 2 (3.77)
DM: 4 (7.55)
Median MS duration (IQR) [years] 10 (13)
DMT (%) No DMT: 3 (5.66)
IFNs: 4 (7.54)
DMF: 21 (39.62)
TFN: 1 (1.89)
GA: 1 (1.89)
FNG: 12 (22.64)
RTX: 9 (16.98)
AZA: 2 (3.77)
COVID-19 diagnosis type (%) RT-PCR: 30 (56.60)
CT: 14 (26.42)
Both: 9 (16.98)
COVID-19 severity (%) No hospitalization: 47 (88.68)
Hospitalization: 6 (11.32)
Mean post-COVID-19 follow-up (SD) [months] 10.58 (2.48)
Outcome Pre-COVID-19 period endpoint Post-COVID-19 period endpoint P value
Median EDSS (IQR) 1.5 (1) 1.5 (1) 0.08*
Number of patients with probable disability progression (%) 10 (18.87) 3 (5.66) 0.04**
Number of patients experiencing relapses (%) 16 (30.19) 11 (20.75) 0.30**
  1. *Wilcoxon signed-rank test
  2. **McNemar test
  3. Abbreviations: SD standard deviation, HTN hypertension, CV cardiovascular, DM diabetes mellitus, MS multiple sclerosis, IQR interquartile range, DMT disease-modifying therapy, IFN interferon, DMF dimethyl fumarate, TFN teriflunomide, GA glatiramer acetate, FNG fingolimod, RTX rituximab, AZA azathioprine, RT-PCR reverse transcription polymerase chain reaction, CT computed tomography, EDSS expanded disability status scale;